Results 1 to 10 of about 6,509 (259)
Background: Drug-induced dry mouth is an adverse reaction that can significantly affect the quality of life and mental state of patients. In this study, we aimed to identify the most common drugs associated with dry mouth using data from the United ...
Dan Xu, Hong Zhu, Meng Wu
doaj +1 more source
Comparative safety profile of biktarvy: insights from a clinical cohort and the FAERS database
BackgroundBiktarvy, a second-generation integrase strand-transfer inhibitor, is approved for treating human immunodeficiency virus (HIV) in patients with no known resistance to its components.
Xinmei Pan +4 more
doaj +1 more source
Congenital anomalies of the external ear can have a significant impact on a child’s development and quality of life. While genetic factors play a crucial role in the etiology of these anomalies, environmental factors such as drug exposure during ...
Xinyu Li +3 more
doaj +1 more source
Background: Janus kinase (JAK) inhibitors are a new class of targeted therapies that block cytokines and the signal transduction and activators of transcription (STAT) pathway.
Sunny Park +5 more
doaj +1 more source
Background: Sevoflurane, an ether-derived inhalational anesthetic widely used for general anesthesia, requires comprehensive safety evaluation. Objectives: This study aimed to identify sevoflurane-associated adverse events and detect unexpected safety ...
Jieyuan Chen, Zhaojun Wang, Songsong Mao
doaj +1 more source
BackgroundRipretinib has been approved for the treatment of gastrointestinal stromal tumors (GIST). As a novel therapy, several adverse reactions remain unidentified, necessitating a thorough safety evaluation.
Sentai Wang +4 more
doaj +1 more source
Mavacamten and atrial fibrillation: assessing the risk through FAERS and meta-analysis
Background Mavacamten is a novel selective cardiac myosin inhibitor indicated for patients with obstructive hypertrophic cardiomyopathy (oHCM). Given its negative inotropic properties, which theoretically reduce myocardial contractility and affect left ...
Lingqing Ding +4 more
doaj +1 more source
IntroductionPacritinib, a selective Janus kinase (JAK) inhibitor, is approved for the treatment of myelofibrosis in adults with severe thrombocytopenia. However, its safety profile in real-world populations remains unclear. The aim of study is provided a
Huiling Zhang +4 more
doaj +1 more source
Triptorelin associated adverse events evaluated using FAERS pharmacovigilance data
Triptorelin, a gonadotropin-releasing hormone(GnRH) agonist, is approved by the US Food and Drug Administration(FDA) for treating advanced prostate cancer, endometriosis, and central precocious puberty(CPP) in children aged ≥ 2 years. This study aimed to
Wei Jia, Tiezhou Wang
doaj +1 more source
A Comprehensive Disproportionality Analysis of Drug-Related Head Injury Reports Using the FAERS Database. [PDF]
Guo J +5 more
europepmc +1 more source

